Methods and compositions associated with administration of an extract of Ganoderma lucidum

• US 7,687,064 B2
• Filed: 09/21/2006
• Issued: 03/30/2010
• Est. Priority Date: 08/06/2001
• Status: Active Grant

• Current Assignee: Academia Sinica (Government of The Republic of China)
• Original Assignee: Academia Sinica (Government of The Republic of China)
• Inventors: Hua, Kuo-Feng, Hsu, Hsien-Yeh, Wong, Chi-Huey
• Primary Examiner(s): Tate; Christopher R
• Assistant Examiner(s): WINSTON, RANDALL O
• Application Number:
  US11/534,204
• Publication Number:
  US 20070105814A1
• Time in Patent Office: 1,286 Days
• Field of Search: None
• US Class Current: 424/195.15
• CPC Class Codes: A61K 36/074 Ganoderma

Abstract

The present disclosure provides methods for increasing the lipopolysaccharide-induced secretion of IL-1 by macrophages, for increasing serum levels of IL-1 in a mammal, for increasing the serum level of IL-1 receptor antagonist (IL-1Ra) in a mammal, for increasing the secretion of IL-1 by a monocyte, for increasing the secretion of IL-1Ra by a monocyte, for increasing the secretion of IL-1Ra by a macrophage, for increasing expression of TLR4 on the surface of a macrophage, for increasing expression of CD14 on the surface of macrophage, for increasing the uptake and clearance of lipopolysaccharide (LPS) by a LPS-stimulated macrophage, and for increasing lipopolysaccharide (LPS)-stimulated activation of at least one of ERK, JNK, and p38 in a macrophage. The methods of the disclosure involve the administration to mammals and immune cells of a fucose-containing glycoprotein fraction from Ganoderma lucidum.

Claims

1. A method comprising administering an effective amount of terminal fucose-containing glycoprotein fraction from Ganoderma lucidum to a lipopolysaccharide (LPS)-stimulated macrophage prior to or during LPS Stimulation to increase the secretion of IL-1 by the macrophage, wherein the terminal fucose-containing fraction is a fraction of Ganoderma lucidum extract prepared by dissolving raw Ganoderma lucidum in a solvent to form a solution, fractioning the solution according to molecular weight, and designating as the terminal fucose-containing glycoprotein fraction the fraction having a light absorbance of about 1.8 at O.D. 625 nm.

2. A method comprising administering an effective amount of a terminal fucose-containing glycoprotein fraction from Ganoderma lucidum to a mammal prior to or during contact of the mammal with a lipopolysacoharide to increase the serum level of IL-1 that is produced in response to introduction of the lipopolysaccharide into the mammal, wherein the terminal fucose-containing fraction is a fraction of Ganoderma lucidum extract prepared by dissolving raw Ganoderma lucidum in a solvent to form a solution, fractioning the solution according to molecular weight, and designating as the terminal fucose-containing glycoprotein fraction the fraction having a light absorbance of about 1.8 at O.D. 625 nm.

3. A method comprising administering an effective amount of a terminal fucose-containing glycoprotein fraction from Ganoderma lucidum to a mammal to increase the serum level of IL-1 receptor antagonist in the mammal, wherein the terminal fucose-containing fraction is a fraction of Ganoderma lucidum extract prepared by dissolving raw Ganoderma lucidum in a solvent to form a solution, fractioning the solution according to molecular weight, and designating as the terminal fucose-containing glycoprotein fraction the fraction having a light absorbance of about 1.8 at O.D. 625 nm.

4. A method comprising administering an effective amount of a terminal fucose containing glycoprotein fraction from Ganoderma lucidum to a monocyte to increase the secretion of IL-1 by the monocyte, wherein the terminal fucose-containing fraction is a fraction of Ganoderma lucidum extract prepared by dissolving raw Ganoderma lucidum in a solvent to form a solution, fractioning the solution according to molecular weight, and designating as the terminal fucose-containing glycoprotein fraction the fraction having a light absorbance of about 1.8 at O.D. 625 nm.

5. A method comprising administering an effective amount of a terminal fucose-containing glycoprotein fraction from Ganoderma lucidum to a monocyte to increase the secretion of IL-1 receptor antagonist by the monocyte, wherein the terminal fucose-containing fraction is a fraction of Ganoderma lucidum extract prepared by dissolving raw Ganoderma lucidum in a solvent to form a solution, fractioning the solution according to molecular weight, and designating as the terminal fucose-containing glycoprotein fraction the fraction having a light absorbance of about 1.8 at O.D. 625 nm.

6. A method comprising administering an effective amount of a terminal fucose-containing glycoprotein fraction from Ganoderma lucidum to a macrophage to increase the secretion of IL-1 receptor antagonist by the macrophage, wherein the terminal fucose-containing fraction is a fraction of Ganoderma lucidum extract prepared by dissolving raw Ganoderma lucidum in a solvent to form a solution, fractioning the solution according to molecular weight, and designating as the terminal fucose-containing glycoprotein fraction the fraction having a light absorbance of about 1.8 at O.D. 625 nm.